Akebia Therapeutics/AKBA

$1.71

9.49%
-
1D1W1MYTD1YMAX

About Akebia Therapeutics

Akebia Therapeutics, Inc. is an integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The Company's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The Company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Ticker

AKBA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Butler

Employees

204

Headquarters

Cambridge, United States
Website
akebia.com

AKBA Metrics

BasicAdvanced
$322.15M
Market cap
-
P/E ratio
-$0.33
EPS
0.77
Beta
-
Dividend rate

What the Analysts think about AKBA

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
153.22% upside
High $5.00
Low $4.00
$1.71
Current price
$4.33
Average price target

AKBA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-34.28% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$42M
-25.4%
Net income
$-14.4M
29.73%
Profit margin
-34.28%
73.92%

AKBA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.88%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.04
-$0.14
-$0.06
-$0.08
-
Expected
-$0.19
-$0.15
-$0.03
-$0.09
-$0.04
Surprise
-78.57%
-6.67%
140%
-5.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Akebia Therapeutics stock

Buy or sell Akebia Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing